# US 2021/0330753 A1 · Methods of treating covid-19 mediated lung damage using surfactants and natural antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330753 A1
- Document ID: US20210330753A1
- Status: Published application
- Kind: A1
- Application number: 17/242,142
- Filed: 2021-04-27
- Published: 2021-10-28
- Earliest claimed: 2020-04-27
- Inventors: Ghassan S Kassab; Carlos A Labarrere
- Web page: https://patentgrep.com/patent/US20210330753A1

## CPC

- A61K 38/395: {Alveolar surfactant peptides; Pulmonary surfactant peptides}
- A61P 31/14: for RNA viruses
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/42: against immunoglobulins
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/52: Constant or Fc region; Isotype
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed is a method of treating respiratory viruses including coronaviruses such as SARS-CoV-2 using surfactant, surfactant protein A and/or surfactant protein D. The surfactant and surfactant protein treatment can be used in combination with immunoglobulin M administered intravenously. Surfactant proteins used in these embodiments, especially surfactant protein D, can be harvested from an exogenous source such as pigs, as they show improved resilience against viruses.

## Claims

### Claim 1

A method of treating a mammalian patient infected with a respiratory virus comprising the step of administering a therapeutically effective amount of surfactant protein.

### Claim 2 (depends on 1)

The method of claim 1 wherein the surfactant protein comprises surfactant protein D (SP-D).

### Claim 3 (depends on 1)

The method of claim 1 wherein the surfactant protein comprises surfactant protein A (SP-A).

### Claim 4 (depends on 1)

The method of claim 1 wherein the surfactant protein comprises a combination of SP-D and SP-A.

### Claim 5 (depends on 2)

The method of claim 2 wherein the SP-D is exogenously derived.

### Claim 6 (depends on 5)

The method of claim 5 wherein the SP-D is porcine derived.

### Claim 7 (depends on 1)

The method of claim 1 wherein the surfactant protein is administered by inhalation.

### Claim 8 (depends on 7)

The method of claim 7 further comprising the step of administering a therapeutically effective amount of Immunoglobulin M natural antibodies (IgM NAbs).

### Claim 9 (depends on 8)

The method of claim 8 wherein the therapeutically effective amount of IgM NAbs is administered intravenously.

### Claim 10

A method of treating a human patient infected with a severe acute respiratory syndrome coronavirus or a variant thereof, comprising the step of administering a therapeutically effective amount of surfactant and porcine SP-D and SPD-A.

### Claim 11 (depends on 10)

The method of claim 10 further comprising the step of administering a therapeutically effective amount of IgM NAbs.

### Claim 12 (depends on 11)

The method of claim 11 wherein the therapeutically effective amount of surfactant is introduced into the airway.

### Claim 13 (depends on 11)

The method of claim 11 wherein the therapeutically effective amount of surfactant is in aerosol form.

### Claim 14 (depends on 13)

The method of claim 13 wherein the therapeutically effective amount of IgM NAabs is introduced intravenously.

### Claim 15

A method of treating a human patient infected with a severe acute respiratory syndrome coronavirus or a variant thereof, comprising the step of administering a therapeutically effective amount of SP-D.

### Claim 16 (depends on 15)

The method of claim 15 further comprising the step of administering a therapeutically effective amount of IgM NAbs.

### Claim 17 (depends on 16)

The method of claim 16 further comprising the step of administering a therapeutically effective amount of SP-A

### Claim 18 (depends on 16)

The method of claim 16 wherein the SP-D is porcine derived.

### Claim 19 (depends on 16)

The method of claim 16 further comprising the step of administering a therapeutically effective amount of surfactant.

### Claim 20 (depends on 15)

The method of claim 15 wherein the severe acute respiratory syndrome coronavirus is SARS-CoV-2.